Updated rheumatoid arthritis treatment recommendations

EULAR – The European Alliance of Rheumatology Associations – has updated its recommendations on disease-modifying treatment for people with rheumatoid arthritis (RA) to take into account developments and new evidence in the field.

Three small changes and one major change have been implemented, the major change involving Janus kinase inhibitors.

The updated recommendations were developed by a multidisciplinary task force of rheumatologists, other health professionals, and patient research partners. 

The information is based on evidence collected from three systematic reviews across efficacy and safety of both DMARDs and glucocorticoids.

WHAT IS EULAR?

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR stands for The European Alliance of Rheumatology Associations.

You can view the full update in pdf form here

SOURCES:

UPDATED Rheumatoid Arthritis #RA TREATMENT RECOMMENDATIONS 2022 update published in the Annals of the Rheumatic Diseases https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1_4229

ORIGINAL EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

https://ard.bmj.com/content/early/2022/11/10/ard-2022-223356